Dextroamphetamine as an Adjunct in Cocaine Treatment - 1
Completed
University of Texas
Phase 2
1997-08-01
The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an
adjunct in cocaine treatment; an evaluation of the ""replacement"" strategy.
Dextroamphetamine as an Adjunct in Cocaine Treatment - 1
Completed
National Institute on Drug Abuse (NIDA)
Phase 2
1997-08-01
The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an
adjunct in cocaine treatment; an evaluation of the ""replacement"" strategy.
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
Completed
University of Texas
Phase 2
1994-09-01
The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an
adjunct in concurrent cocaine and opiate dependent patients.
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
Completed
National Institute on Drug Abuse (NIDA)
Phase 2
1994-09-01
The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an
adjunct in concurrent cocaine and opiate dependent patients.
A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)
Completed
Ironshore Pharmaceuticals and Development, Inc
Phase 1/Phase 2
2013-07-01
The main purpose of this study is to determine the rate and extent of absorption of one or
more modified release formulations of amphetamine (HLD100) in both adolescents and children
with ADHD.
A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD
Completed
Ironshore Pharmaceuticals and Development, Inc
Phase 2
2016-08-01
The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady
state (following up to 5 weeks of treatment) in children using an outpatient, single-center,
open-label, flexible dose-escalation study design.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
